Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients

BACKGROUND: In monarchE and Postoperative Therapy with Endocrine and TS‐1 (POTENT) trials, abemaciclib and S‐1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the criteria are at high risk of recurrence compared to no...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Muhan, Takada, Mamoru, Yamada, Hideyuki, Fujimoto, Hiroshi, Sakakibara, Junta, Yamamoto, Hiroto, Nagashima, Takeshi, Ohtsuka, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315737/
https://www.ncbi.nlm.nih.gov/pubmed/37162105
http://dx.doi.org/10.1002/cam4.6006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315737/
https://www.ncbi.nlm.nih.gov/pubmed/37162105
http://dx.doi.org/10.1002/cam4.6006

Ejemplares similares